BOLTON SECURITIES CORPORATION’s Madrigal Pharmaceuticals MDGL Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.51K	Buy	+3	New	+$1.58K	﹤0.01%	2131

Other funds holding MDGL

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's MDGL Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 3 shares worth $1.51K. The stake represents ﹤0.01% of the portfolio and ranks #2131 among its holdings.

266 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

BOLTON SECURITIES CORPORATION held 3 shares of Madrigal Pharmaceuticals worth $1.51K as of Q3 2026.
Madrigal Pharmaceuticals was a new BOLTON SECURITIES CORPORATION position in Q3 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q3 2026, its #2131 holding.
266 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.